Share on StockTwits

Celsion (NASDAQ:CLSN) Director Frederick J. Fritz bought 4,000 shares of Celsion stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $12,800.00. Following the completion of the acquisition, the director now directly owns 30,311 shares of the company’s stock, valued at approximately $96,995. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Paradigm Capital raised their price target on shares of Celsion from $12.50 to $13.50 in a research note on Thursday, July 17th. They now have a “buy” rating on the stock.

Celsion (NASDAQ:CLSN) traded down 2.81% on Friday, hitting $3.11. 146,744 shares of the company’s stock traded hands. Celsion has a 52 week low of $2.82 and a 52 week high of $6.6216. The stock’s 50-day moving average is $3.24 and its 200-day moving average is $3.39. The company’s market cap is $53.5 million.

Celsion (NASDAQ:CLSN) last released its earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.32) by $0.06. On average, analysts predict that Celsion will post $-1.33 earnings per share for the current fiscal year.

Celsion Corporation (NASDAQ:CLSN) is an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer.

Receive News & Ratings for Celsion Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Co and related companies with Analyst Ratings Network's FREE daily email newsletter.